Advertisement

C679X loss-of-function PCSK9 variant lowers fasting glucose levels in a black South African population: A longitudinal study

  • Tinashe Chikowore
    Correspondence
    Corresponding author at: MRC/Wits Developmental Pathways for Health Research Unit, Department of Pediatrics, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa.
    Affiliations
    MRC/Wits Developmental Pathways for Health Research Unit, Department of Pediatrics, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa

    Division of Human Genetics, School of Pathology, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa

    DST-NRF Centre of Excellence in Mathematical and Statistical Sciences (CoE-MaSS), University of the Witwatersrand, Johannesburg, South Africa
    Search for articles by this author
  • Marike Cockeran
    Affiliations
    School of Mathematical and Statistical Sciences, North West University, Potchefstroom, North West Province 2520, South Africa
    Search for articles by this author
  • Karin R. Conradie
    Affiliations
    Center for Excellence in Nutrition, North West University, Potchefstroom, North West Province 2520, South Africa
    Search for articles by this author
  • Tertia van Zyl
    Affiliations
    Center for Excellence in Nutrition, North West University, Potchefstroom, North West Province 2520, South Africa
    Search for articles by this author
Published:September 15, 2018DOI:https://doi.org/10.1016/j.diabres.2018.09.012

      Abstract

      Aims

      To determine the longitudinal association of the loss-of-function (LOF) PCSK9 variants (C679X and A443T), proxies of PCSK9 inhibitor drugs, with LDL-C, fasting glucose and glycated hemoglobin.

      Methods

      We conducted a five year, longitudinal study, nested within the Prospective Urban and Rural Epidemiology study, among 737 apparently healthy, male and female black South Africans of the North West province. Genotyping of the C679X and A443T PCSK9 variants was achieved using Taqman assays from Applied Biosystems. Generalized estimating equations were used to determine longitudinal association of the A443T and C679X PCSK9 variants with LDL–C, fasting glucose and glycated hemoglobin.

      Results

      C679X and A443T variant carriers were associated with significant reductions in LDL-C of −0.98(−1.29, −0.67) mmol/L; p < 0.001) and −0.39(−0.57, −0.20) mmol/L; p < 0.001) respectively, compared to the non-carriers. Only C679X variant was independently associated with reductions in fasting glucose of −0.37 (−0.61, −0.13) mmol/L; p = 0.002) compared to non-carriers. However, the association of the selected variants with glycated hemoglobin were not significant. C679X and A443T carriers were associated with −0.07 (−0.23, 0.09) %; p = 0.400), 0.05 (−0.13, 0.22) %; p = 0.599) of glycated haemoglobin respectively.

      Conclusion

      Our results indicated that carriers of A443T and C679X variants exhibit sustained low LDL-C levels over 5 years and have varied effects on T2D biomarkers compared to non-carriers.

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Diabetes Research and Clinical Practice
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Andersson C.
        • Lyass A.
        • Vasan R.S.
        • Massaro J.M.
        • D'Agostino Sr., R.B.
        • Robins S.J.
        Long-term risk of cardiovascular events across a spectrum of adverse major plasma lipid combinations in the Framingham Heart Study.
        Am Heart J. 2014; 168e1
        • Roth E.M.
        • McKenney J.M.
        • Hanotin C.
        • Asset G.
        • Stein E.A.
        Atorvastatin with or without an antibody to PCSK9 in primary hypercholesterolemia.
        N Engl J Med. 2012; 367: 1891-1900
        • Baum S.J.
        • Toth P.P.
        • Underberg J.A.
        • Jellinger P.
        • Ross J.
        • Wilemon K.
        PCSK9 inhibitor access barriers-issues and recommendations: improving the access process for patients, clinicians and payers.
        Clin Cardiol. 2017; 40: 243-254
        • Chang Y.
        • Robidoux J.
        Dyslipidemia management update.
        Curr Opin Pharmacol. 2017; 33: 47-55
        • Schmidt A.F.
        • Swerdlow D.I.
        • Holmes M.V.
        • Patel R.S.
        • Fairhurst-Hunter Z.
        • Lyall D.M.
        • et al.
        PCSK9 genetic variants and risk of type 2 diabetes: a mendelian randomisation study.
        Lancet Diabetes Endocrinol. 2017; 5: 97-105
        • Sattar N.
        • Preiss D.
        • Robinson J.G.
        • Djedjos C.S.
        • Elliott M.
        • Somaratne R.
        • et al.
        Lipid-lowering efficacy of the PCSK9 inhibitor evolocumab (AMG 145) in patients with type 2 diabetes: a meta-analysis of individual patient data.
        Lancet Diabetes Endocrinol. 2016; 4: 403-410
        • Hoe E.
        • Hegele R.A.
        Lipid management in diabetes with a focus on emerging therapies.
        Can J Diabetes. 2015; 39: S183-S190
        • Lee J.
        • Hegele R.A.
        PCSK9 inhibition and diabetes: turning to Mendel for clues.
        Lancet Diabetes Endocrinol. 2017; 5: 78-79
        • Preiss D.
        • Seshasai S.R.
        • Welsh P.
        • Murphy S.A.
        • Ho J.E.
        • Waters D.D.
        • et al.
        Risk of incident diabetes with intensive-dose compared with moderate-dose statin therapy: a meta-analysis.
        JAMA. 2011; 305: 2556-2564
        • Cohen J.C.
        • Emerging L.D.L.
        Therapies: using human genetics to discover new therapeutic targets for plasma lipids.
        J Clinic Lipidol. 2013; 7: S1-S5
        • Lotta L.A.
        • Sharp S.J.
        • Burgess S.
        • Perry J.R.
        • Stewart I.D.
        • Willems S.M.
        • et al.
        Association between low-density lipoprotein cholesterol-lowering genetic variants and risk of type 2 diabetes: a meta-analysis.
        JAMA. 2016; 316: 1383-1391
        • Hallman D.M.
        • Srinivasan S.R.
        • Chen W.
        • Boerwinkle E.
        • Berenson G.S.
        Relation of PCSK9 mutations to serum low-density lipoprotein cholesterol in childhood and adulthood (from The Bogalusa Heart Study).
        Am J Cardiol. 2007; 100: 69-72
        • Bonnefond A.
        • Yengo L.
        • Le May C.
        • Fumeron F.
        • Marre M.
        • Balkau B.
        • et al.
        The loss-of-function PCSK9 p.R46L genetic variant does not alter glucose homeostasis.
        Diabetologia. 2015; 58: 2051-2055
        • Teo K.
        • Chow C.K.
        • Vaz M.
        • Rangarajan S.
        • Yusuf S.
        Group PI-W. The Prospective Urban Rural Epidemiology (PURE) study: examining the impact of societal influences on chronic noncommunicable diseases in low-, middle-, and high-income countries.
        Am Heart J. 2009; 158: e1
        • Chikowore T.
        • Pisa P.T.
        • van Zyl T.
        • Feskens E.J.
        • Wentzel-Viljoen E.
        • Conradie K.R.
        Nutrient patterns associated with fasting glucose and glycated hemoglobin levels in a black South African population.
        Nutrients. 2017; : 9
        • Cohen J.
        • Pertsemlidis A.
        • Kotowski I.K.
        • Graham R.
        • Garcia C.K.
        • Hobbs H.H.
        Low LDL cholesterol in individuals of African descent resulting from frequent nonsense mutations in PCSK9.
        Nat Genet. 2005; 37: 161-165
        • Kotowski I.K.
        • Pertsemlidis A.
        • Luke A.
        • Cooper R.S.
        • Vega G.L.
        • Cohen J.C.
        • et al.
        A spectrum of PCSK9 alleles contributes to plasma levels of low-density lipoprotein cholesterol.
        Am J Hum Genet. 2006; 78: 410-422
        • Huang C.C.
        • Fornage M.
        • Lloyd-Jones D.M.
        • Wei G.S.
        • Boerwinkle E.
        • Liu K.
        Longitudinal association of PCSK9 sequence variations with low-density lipoprotein cholesterol levels: the Coronary Artery Risk Development in Young Adults Study.
        Circulation Cardiovascular Genet. 2009; 2: 354-361
        • Hooper A.J.
        • Marais A.D.
        • Tanyanyiwa D.M.
        • Burnett J.R.
        The C679X mutation in PCSK9 is present and lowers blood cholesterol in a Southern African population.
        Atherosclerosis. 2007; 193: 445-448
        • Cohen J.C.
        • Boerwinkle E.
        • Mosley Jr., T.H.
        • Hobbs H.H.
        Sequence variations in PCSK9, low LDL, and protection against coronary heart disease.
        N Engl J Med. 2006; 354: 1264-1272
        • Zhao Z.
        • Tuakli-Wosornu Y.
        • Lagace T.A.
        • Kinch L.
        • Grishin N.V.
        • Horton J.D.
        • et al.
        Molecular characterization of loss-of-function mutations in PCSK9 and identification of a compound heterozygote.
        Am J Hum Genet. 2006; 79: 514-523
        • Benjannet S.
        • Rhainds D.
        • Hamelin J.
        • Nassoury N.
        • Seidah N.G.
        The proprotein convertase (PC) PCSK9 is inactivated by furin and/or PC5/6A: functional consequences of natural mutations and post-translational modifications.
        J Biol Chem. 2006; 281: 30561-30572
        • Lakoski S.G.
        • Lagace T.A.
        • Cohen J.C.
        • Horton J.D.
        • Hobbs H.H.
        Genetic and metabolic determinants of plasma PCSK9 levels.
        J Clin Endocrinol Metab. 2009; 94: 2537-2543
        • Eisenga M.F.
        • Zelle D.M.
        • Sloan J.H.
        • Gaillard C.
        • Bakker S.J.L.
        • Dullaart R.P.F.
        High serum PCSK9 is associated with increased risk of new-onset diabetes after transplantation in renal transplant recipients.
        Diabetes Care. 2017; 40: 894-901
        • Baass A.
        • Dubuc G.
        • Tremblay M.
        • Delvin E.E.
        • Loughlin J.
        • Levy E.
        • et al.
        Plasma PCSK9 is associated with age, sex, and multiple metabolic markers in a population-based sample of children and adolescents.
        Clin Chem. 2009; 55: 1637